FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 92 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French MOST POPULAR The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously... August 3, 2021 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... May 24, 2019 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to... Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow Single Mom Has To Beg For Rides To Doctor For Son... One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among...
